Readystate Asset Management LP Makes New $375,000 Investment in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Readystate Asset Management LP acquired a new position in Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 45,400 shares of the company's stock, valued at approximately $375,000. Readystate Asset Management LP owned 0.74% of Aligos Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its holdings in shares of Aligos Therapeutics by 19.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company's stock valued at $569,000 after acquiring an additional 2,306 shares in the last quarter. Geode Capital Management LLC grew its holdings in Aligos Therapeutics by 13.3% during the fourth quarter. Geode Capital Management LLC now owns 27,253 shares of the company's stock worth $1,086,000 after buying an additional 3,197 shares in the last quarter. Trexquant Investment LP bought a new position in Aligos Therapeutics in the 4th quarter valued at $2,751,000. Wells Fargo & Company MN bought a new position in Aligos Therapeutics in the 4th quarter valued at $869,000. Finally, Tower Research Capital LLC TRC grew its stake in Aligos Therapeutics by 2,073.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company's stock valued at $26,000 after purchasing an additional 622 shares during the period. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Price Performance

Shares of NASDAQ ALGS traded down $0.37 during trading on Thursday, reaching $8.91. 38,504 shares of the stock traded hands, compared to its average volume of 85,029. The company has a 50-day moving average of $7.36 and a 200-day moving average of $12.65. The stock has a market capitalization of $54.44 million, a P/E ratio of -0.51 and a beta of 2.77. Aligos Therapeutics, Inc. has a 52-week low of $3.76 and a 52-week high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($2.11) earnings per share for the quarter, topping analysts' consensus estimates of ($2.80) by $0.69. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.33 million. Aligos Therapeutics had a positive return on equity of 14.67% and a negative net margin of 1,628.75%. Analysts expect that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Aligos Therapeutics in a research note on Monday, March 31st.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).